Receipt of BNT162b2 KP.2 Vaccine and COVID-19 CVS MinuteClinic Visits in US Adults
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Using a test-negative design, we modeled the association between receipt of BNT162b2 KP.2 vaccine and symptomatic COVID-19 among adults testing for SARS-CoV-2 at walk-in clinics in a large US retail pharmacy chain (9/5/2024–12/8/2024). At a median of 37 days post-vaccination, those who received BNT162b2 KP.2 were 48% less likely to test positive.
